Roche offers significantly reduced pricing for direct supplies of Invirase and Viracept from the headquarters in Basel to low and lower middle income countries, as classified by the World Bank

Summary of reduced prices available for direct purchase from Roche Basel. Available to all low income and lower middle income countries. (Prices effective as of 1st August 2006 )
Invirase® 200 mg Price per pack (270 x 200mg capsules) / CHF	Invirase® 500 mg Price per pack (120 x 500mg tablets) / CHF	Viracept® Price per pack (270 x 250mg tablets) / CHF	Viracept® Paediatric powder Price per 144g pack / CHF
200.00	222.00	200.00	45.00

Low Income (LI) Economies:
List is correct as of October 2008
Source: World Bank classification of economies ^{1, 2}:
Korea Dem. Rep., Kyrgyz Republic, Pakistan, Papua New Guinea, Tajikistan, Uzbekistan, Vietnam.

Lower Middle Income (LMI) Economies ^1,2:
List is correct as of October 2008
Albania, Algeria, Armenia, Azerbaijan, Belarus, Bolivia, Bosnia and Herzegovina, China, Colombia,  Dominican Republic, Ecuador, Egypt, El Salvador,  Georgia, Guatemala, Guyana, Honduras, India, Indonesia, Iran, Iraq, Jordan, Macedonia, Marshall Islands, Micronesia Federal States, Moldova, Mongolia, Morocco, Nicaragua, Paraguay, Peru, Philippines, Samoa, Sri Lanka,  Syrian Arab Republic, Thailand, Tonga, Tunisia, Turkmenistan, Ukraine, West Bank and Gaza.

¹ Those not otherwise classified as “Least Developed” by the United Nations.
² Other than those already listed in the list of sub-Saharan countries where no profit prices apply.
For further information on WHO defined essential medicines see: http://www.who.int/medicines/publications/essentialmedicines/en/
Products on the WHO list of Pilot Procurement, Quality and Sourcing Project: Access to HIV/AIDS drugs and diagnostics of acceptable quality (edition of 9 September 2002) have an asterisk (*) next to the price. Incoterms vary according to manufacturers.

Roche’s commitment to increasing access to HIV healthcare globally
Roche is committed to increasing access to HIV healthcare globally through the development of healthcare solutions that are sustainable and have a long-term impact, particularly on the lives of those in the Least Developed Countries and sub-Saharan Africa.  Roche is a founding member of the Accelerating Access Initiative, which aims to provide sustainable access to HIV care and treatment in resource limited countries. 

Terms and Conditions associated with the Pricing Policy for SSA, LDCs and Low Income and Lower Middle Income countries

• Minimum order and delivery amount per shipment is CHF 10,000.
• Under circumstances where Roche is requested to provide delivery, distribution costs as well as import taxes and duties must be added.  Local retail prices are therefore higher than these ex-RocheBaselprices.
• These prices are provided subject to the conditions that the drug will not be diverted or re-exported to other countries not qualifying for the specified price
• FCA Basel (Incoterms 2000)
• CAD (Cash Against Documents/Cash on Delivery) 30 days at sight
• Swiss Franc invoicing (CHF)
• All purchasers placing orders for reduced priced HIV medicines from Roche Basel will be required to provide the final delivery destination and recipient name in order to enable tracking and monitoring of product supply

Roche Company contact for ordering and logistics issues only:

Sandra Torriani
Demand Manager
PTGS-O
F.Hoffmann-La Roche Ltd., Basel
Building 237/2.17
CH 4303 Switzerland
Phone: +41 61 688 9390
Fax: +41 61 687 1815
Email: [email protected]
For other information concerning eligibility and pricing please contact:

René Imhof
Head of Operational Pricing (PBSO)
Phone: +41 61 687 3930
Fax: +41 61 688 1525
Email: [email protected]